NCT02798692View on ClinicalTrials.gov

Trial to Evaluate Safety and Immunogenicity of a Vaccine Against HCMV

PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

May 31, 2017

Study Completion Date

March 31, 2018

Conditions
Cytomegalovirus Infection
Interventions
BIOLOGICAL

Low dose HB-101

Three intra muscular administrations at Day 0, Month 1 and Month 3

BIOLOGICAL

Medium dose HB-101

Three intra muscular administrations at Day 0, Month 1 and Month 3

BIOLOGICAL

High dose HB-101

Three intra muscular administrations at Day 0, Month 1 and Month 3

BIOLOGICAL

Placebo

Three intra muscular administrations at Day 0, Month 1 and Month 3. The diluent is used as placebo.

Trial Locations (1)

9000

Center for Vaccinology Ghent, Ghent

Sponsors
All Listed Sponsors
collaborator

Centre for Vaccinology Ghent - CEVAC

UNKNOWN

lead

Hookipa Biotech GmbH

INDUSTRY